FILTER
FILTERED INTERVIEW RESULTS
George Ankomah
PARTNER, DELOITTE GHANA
"Deloitte is a key stakeholder to the industry, providing input in the development of various mining laws over the years."
Adama Soro
PRESIDENT, CHAMBER OF MINES BURKINA FASO
"Companies like Endeavour Mining, IAMGOLD, Orezone, Trevali or Roxgold (Fortuna Silver Mines) and many others, continue to invest in the country, adding their vote of confidence in the potential of Burkina Faso."
Craig Roberts
CEO, NEW FOUND GOLD
"We have eight drills currently running and may expand this further to accelerate drill testing of a very large prospective target area."
David Christie
PRESIDENT AND CEO, ORFORD MINING
"When you look at Orford, it has potential for multiple discoveries on a massive land position in what we think is a new gold district."
Rahul Paul
PRESIDENT AND INTERIM CEO, RADISSON MINING RESOURCES
"We are located in elephant country, with a number of large producers within 70 km of O’Brien."
David Russell
PRESIDENT AND CEO, GALLEON GOLD CORP.
"Galleon Gold has a significant land package in a great district that has amazing infrastructure for mining."
Doug Ramshaw
PRESIDENT, MINERA ALAMOS
"Minera Alamos is now at the far peak of the curve, which is a great differentiator as very few explorers and developers get to be producers."
Adolfo Vera
PRESIDENTE y CEO, SOUTHERN PEAKS MINING
Southern Peaks Mining shares the company’s latest developments at its Condestable and Ariana projects in Peru (Spanish interview)
Gianflavio Carozzi
CEO, AESA
Underground contractor AESA has formed a JV with Redpath for Newmont’s Yanacocha Sulfides project (Spanish interview)
Christopher Grove
PRESIDENT, COMMERCE RESOURCES CORP.
"Commerce owns 100% of the Ashram Rare Earth Elements/Fluorspar deposit, which is the largest defined monazite dominant resource in North America."
MACIG
SPANISH
SUBSCRIBE TO OUR NEWSLETTER
RECENT PUBLICATIONS
United States Life Sciences 2025 - Digital Interactive
Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
PARTNER EVENTS
SUBSCRIBE TO OUR
NEWSLETTER
- Get GBR content delivered to your inbox
- Receive industry based news
- Completely free, e-mail only
